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1. Introduction
Metabolic Syndrome (MetS) consists of physical con-
ditions and metabolic abnormalities commonly found in 
association with increased risk for development of type-2 
diabetes mellitus (T2DM), cardiovascular disease (CVD) 
and other medical conditions [1]. Worldwide prevalence 
of MetS ranges from <10% to as high as 84%. Higher 
socio-economic status, sedentary lifestyle and high Ba-
sal Metabolic Index (BMI) were significantly associated 
with MetS. The prevalence of metabolic syndrome is 
increasing in India, both in the urban and rural areas. It 
has escalated in different parts of India to figures now 
ranging from 11% to 41% [1]. Furthermore, the prevalence 
is 1.5 -2 times higher in women compared to men [2,3]. 
The proposed central abnormality associated with MetS 
is insulin resistance (IR) [4]. Insulin secretory capacity can 
be assessed by measuring C-peptide. Serum C-peptide is 
commonly used as a surrogate marker of endogenous in-
sulin secretory capacity but due to perceived practical re-
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To assess the correlation between urinary C peptide creatinine ratio 
with serum C peptide, serum insulin and its correlation with clinical and 
biochemical parameters of metabolic syndrome. A total of 100 subjects 
more than 18 years of age with metabolic syndrome according to ATP III 
criteria with 100 controls were included in a prospective observational 
study for a period of 1.5 years. Individual parameters of metabolic 
syndrome was higher in females with hypertriglyceridemia was most 
common and hyperglycaemia least common parameter of metabolic 
syndrome. Fasting urinary C peptide creatinine ratio and Stimulated urinary 
C peptide correlate significantly with fasting serum C peptide (p<0.01), 
stimulated serum C peptide (p<0.01), serum fasting insulin (p<0.01) and 
HOMA IR (p<0.01). A fasting urinary C peptide creatinine ratio of more 
than 1.8 nmol/mmol, stimulated urinary C peptide creatinine ratio more 
than 2.8 nmol/mmol and HOMA IR >2.7 can be used as a parameter to 
distinguish individual with and without metabolic syndrome. Urinary C 
peptide creatinine ratio correlate with serum C peptide and parameters 
of metabolic syndrome and can be used as a non-invasive simple tool to 






Type 2 diabetes mellitus
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strictions associated with sample collection its widespread 
use is limited. A 24 hour urine C-peptide (UCP) excretion 
provides an accurate means of assessing beta cell-secreto-
ry capacity and correlate with both fasting and stimulated 
serum insulin and C-peptide [5,6]. However, obtaining an 
accurate and complete 24 hour urine collection has limited 
the utility of this test [7-9]. Creatinine adjusted urine C-pep-
tide concentration enables the use of ‘spot’ urine samples 
in place of 24-h urine collection. Several workers have 
established that high serum C peptide levels coexist with 
hyperinsulinemia in metabolic syndrome but there are 
very few studies on correlation of urinary C peptide cre-
atinine ratio with metabolic syndrome and so we decided 
to explore the correlation of urinary C-peptide creatinine 
ratio in patients with metabolic syndrome and also its 
correlation with parameters of metabolic syndrome at our 
place.
2. Materials and Methods
A prospective observational study was conducted from 
January 2018 to June 2019 on subjects attending Guwa-
hati Medical College. For calculating the sample size, 
at 10% population prevalence and 5.8% margin of error 
the required minimum sample size was 100. Total 100 
Individuals more than 18 years of age fulfilling criteria 
for metabolic syndrome according to ATP III with 100 
control subjects were included. All agreed to participate 
and gave oral and written consent. Criteria for metabolic 
syndrome according to ATP III includes any three of five 
criteria. Waist circumference >90 cm (M), >80 cm (F), 
Fasting glucose ≥100 mg/dl, Triglycerides≥150 mg/dl, 
HDL cholesterol<40 mg/dl (M), <50 mg/dl (F), Blood 
pressure->130 mm Hg systolic or>85 mm Hg diastolic. 
Exclusion criteria includes patients with chronic kidney 
disease (egfr<60 ml/min), post pancreatectomy, patients 
on insulin and sulphonylureas. Detailed history and thor-
ough clinical examination were done as per proforma. 
Anthropometric data collected from all the patients and 
includes height and weight measurement. BMI calculated 
for all patients and recorded, waist circumference and 
hip circumference was recorded in all patients and waist: 
Hip ratio calculated. Routine investigation like Haemo-
globin (Hb), Total Leucocytes Count (TLC), Differential 
Leucocytes Count (DLC), Erythrocyte Sedimentation 
Rate (ESR), Liver Function Test (LFT), Kidney Function 
Test (KFT), Plasma glucose, HBA1C, eGFR Calculated, 
Thyroid function test, ECG, Chest x ray, USG abdomen. 
Markers of metabolic syndrome like hsCRP, serum uric 
acid, fasting lipid profile (Triglycerides, Total cholesterol, 
High Density lipoprotein, Low Density lipoprotein), fast-
ing blood glucose (FBG) done in all cases. 
Ethics approval
The Institutional Review Board of Guwahati Medical 




Stimulated urine sample collected to assess maximum 
endogenous C-peptide response. Patients were asked to 
collect second void fasting urine sample after voiding ear-
ly morning fasting urine. 75 gm of Glucose in water to be 
taken within 5-10 minute, patient should not eat anything 
else for the next 2 hours unless you have a hypoglycaemic 
episode, in which case test should be done on another day. 
Patient can drink water freely throughout the duration 
of the collection. 2 hours after collect urine and send for 
analysis. Sample processing done immediately for fasting 
C-peptide (Serum & Urine), Stimulated C peptide (120 
minutes post glucose) (Serum & Urine), fasting urinary C 
peptide and stimulated urinary C peptide creatinine ratio 
calculated and finding recorded, fasting serum Insulin. 
HOMA IR calculated using fasting serum insulin and fast-
ing plasma glucose and findings recorded. The C peptide 
and serum insulin measurement was done by electrochem-
iluminescence immunoassay “ECLIA” is intended for use 
on Elecsys and cobas e immunoassay analyzers. Urinary 
creatinine was assessed by Jaffé method using Roche/Hi-
tachi cobas c systems..
Statistical analysis
Statistical analysis was done using SPSS software. The 
continuous data were expressed as mean± standard devia-
tion (SD) and range. Correlation was established by Pear-
son correlation method. Multilinear regression analysis 
was used to determine association between dependent and 
independent variable.
Patient and Public Involvement (PPI) statement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our re-
search.
4. Results
Our study reveals significant gender differences with 
higher prevalence of metabolic syndrome in females as com-
pared to males. Out of total 100 patients, 43 (43%) patients 
were male and 57 (57%) were females with higher rates of 
metabolic syndrome in elderly. Females have significantly 
DOI: https://doi.org/10.30564/jer.v3i2.3451
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higher baseline fasting urinary C peptide and fasting serum C 
peptide as compared to male (8.76±2.25 nmol/mmol; p-0.04; 
1.74±0.65 nmol/mmol, p<0.0001). Similarly, fasting 
urinary C peptide creatinine ratio, stimulated urinary C 
peptide creatinine ratio (3.4±1.12 nmol/mmol, p<0.0001; 
5.66±2 nmol/mmol p-0.02), serum insulin and HOMA IR 
(12.85±2.43 IU, p-0.04; 2.65±0.62, p-0.04) were statisti-
cally significant in female subjects as compared to males. 
Table 1 shows the baseline characteristics of patients and 
control subjects. Hypertriglyceridemia was the most com-
mon and hyperglycaemia least common component of 
metabolic syndrome in our study group (Table 2). There 
was significant positive correlation between fasting uri-
nary C peptide creatinine ratio with Serum triglyceride 
(r-0.721, p<0.01), CRP(r-0.783, p<0.01), fasting serum 
C peptide (r-0.422, p<0.01) (Figure 1), stimulated serum 
C peptide (r-0.663, p<0.01) (Figure 2), Serum Insulin 
(r-0.528, p<0.01), HOMA IR (r-0.626,p<0.01), FBS (r-
Table 1. Baseline characteristics between cases and control
Variable Control Cases P value
Age 36.69±12.9 35.95±12.1 0.672
Serum creatinine 0.82±0.1 0.83±0.1 0.578
Weight 63.69±8.83 84.82±12.33 <0.0001
EGFR 106.8±14.3 107.76±14.08 0.634
AST 19.27±4.25 40.79±9.14 <0.0001
ALT 17.32±3.87 40.94±13.84 <0.0001
Cholesterol 124.71±18.93 175.48±35.83 <0.0001
LDL 134.08±24.18 146.3±35.94 0.005
HDL 35.5±7.74 36.21±7.99 0.53
TG 207.27±44.16 208.27±47.72 0.878
Uric acid 6.01±0.85 6.02±0.87 0.902
hs-CRP 7.2±1.4 7.33±1.64 0.562
FBS 81.1±9.16 82.47±11.32 0.348
PPBS 128.96±9.02 134.78±13.16 <0.0001
Fasting urinary C peptide(nmol) 2.21±0.42 8.36±2.22 <0.0001
Stimulated urinary C peptide (nmol) 3.55±0.59 13.76±2.58 <0.0001
Urine creatinine(mmol) 2.73±0.69 2.83±0.84 0.371
Fasting serum C peptide (nmol) 0.87±0.29 1.51±0.73 <0.0001
Stimulated serum C peptide(nmol) 1.39±0.45 2.51±0.75 <0.0001
Fasting urinary C peptide creatinine ratio(nmol/mmol) 1.2±0.32 3.12±1.08 <0.0001
Stimulated urinary C peptide creatinine ratio(nmol/mmol) 2.05±0.37 5.28±1.86 <0.0001
Waist circumference(cm) 79.98±7.36 109.19±12.32 <0.0001
Hip circumference(cm) 85.62±7.71 105.88±7.57 <0.0001
W:H ratio 0.94±0.05 1.05±0.05 <0.0001
Height(cm) 161.98±9.33 162.58±9.58 0.654
Weight(kg) 65.28±9.6 84.82±12.33 <0.0001
BMI (kg/m2) 24.63±2.34 31.97±3.31 <0.0001
HBA1C (%) 5.37±0.27 5.53±0.5 0.005
Fasting serum insulin (MIU/L) 10.98±1.46 12.43±2.32 <0.0001
HOMA IR 2.19±0.33 2.54±0.62 <0.0001
EGFR-Estimated glomerular filtration rate, AST-Aspartate transaminase, ALT-Alanine transaminase, FBS-Fasting blood sugar, PPBS-
Post prandial blood sugar, TG-Triglycerides, LDL-Low density lipoprotein, HDL-High density lipoprotein, hs-CRP-High sensitivity 
C-reactive protein, BMI-Body mass index, HOMA IR-Homeostatic model assessment -Insulin Resistance
DOI: https://doi.org/10.30564/jer.v3i2.3451
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0.384, p<0.01), PPBS (R-0.536 P<0.01), Waist: Hip 
ratio(r-0.421, p<0.01) (Table 3). Similarly there was sig-
nificant negative correlation between fasting urinary C 
peptide creatinine ratio with HDL (r-0.195, p<0.01) (Table 
4). Stimulated urinary C peptide creatinine ratio showed 
significantly positive correlation with Serum triglyceride 
(r-0.735, p<0.01), CRP (r-0.758, p<0.01), fasting serum 
C peptide (r-0.399, p<0.01) (Figure 3), stimulated serum 
C peptide (r-0.545, p<0.01) (Figure 4), Serum Insulin (r-
0.580, p<0.01), HOMA IR (r-0.634, p<0.01), FBS (r-0.331, 
p<0.01), PPBS (r-0.386 p<0.01), Waist: Hip ratio (r-0.330, 
p-0.001) (Table 5&6). On multiple linear regression 
analysis with fasting urinary C peptide creatinine ratio as 
dependent variable there was significant association with 
stimulated serum C peptide (p-<0.0001), Serum FBS (p-
0.04), Serum triglycerides (p<0.0001) and fasting serum 
insulin (p<0.0001) (Table 7). On multiple linear regres-
sion analysis with stimulated urinary C peptide creatinine 
ratio as dependent variable there was significant associ-
ation with stimulated serum C peptide (p-0.03), Serum 
triglycerides (p<0.0001) and fasting serum insulin (p-
<0.0001) (Table 8). The receiver operating characteristic 
(ROC) curve of fasting and stimulated urinary C peptide 
creatinine ratio for the diagnosis of Metabolic syndrome 
was depicted and the area under the curve (AUC) was 
calculated (Figure 5). The ROC curve identified a cut-off 
of fasting UCPCR ≥ 1.8 nmol/mmol and stimulated UCP-
CR >2.8 nmol/mmol for discriminating individual with 
metabolic syndrome from control population (AUC 0.980 
& 0.999) with 100% sensitivity and specificity. The ROC 
curve identified a cut-off of HOMA IR ≥2.7 for discrim-
inating patients with metabolic syndrome from control 
population (AUC 0.66) with 30% sensitivity and 95% 
specificity.
Table 2. Distribution of component metabolic syndrome 
among subjects(N-100) according to ATP III criteria
Component Male (N-43) Female (N-57) Total
FBS >100mg/dl 2(25%) 6(75%) 8(100%)
TG >150mg/dl 41(43.2%) 54(56.8%) 95(100%)
HDL
 <40mg/dl (Males) 32 (74.4%) - 43(100.0%)
<50mg/dl (Females) - 47 (82.5%) 57 (100.0%)
Waist Circumference 
Males >90cm 38 (88.4%) - 43 (100.0%)
Females >80cm - 51 (89.5%) 57(100.0%)
Systolic blood pressure 
(>130mmHg)
18(43.9%) 23(56.1%) 41(100%)
Diastolic blood pressure 
(>85mmHg)
33(49.3%) 34(50.7%) 67(100%)
Table 3. Pearson correlation: Fasting Urinary C peptide 
creatinine ratio in metabolic syndrome(N-100)
Parameter Correlation coefficient r P Value
Fasting serum C peptide(nmol) 0.422 <0.01
Stimulated serum C peptide(nmol) 0.663 <0.01
Serum Insulin (MIU/L) 0.528 <0.01
HOMA IR 0.626 <0.01
Table 4. Pearson correlation: Fasting urinary C peptide 
creatinine ratio in metabolic syndrome(N-100)
Parameter Correlation coefficient r P Value
Low Density Lipoprotein(mg/dl) 0.078 0.44
High Density Lipoprotein(mg/dl) -.195 <0.01
Triglyceride(mg/dl) 0.721 <0.01
Uric acid(mg) -0.011 0.913
hs-CRP (mg) 0.783 <0.01
Fasting Blood Sugar(mg/dl) 0.384 <0.01
Post Prandial Blood Sugar(mg/dl) 0.536 <0.01
HBA1C (%) 0.099 0.105
Waist Circumference(cm) 0.114 0.261
Waist: Hip Ratio 0.421 < 0.01
BMI (kg/m2) 0.188 0.06
Table 5. Pearson correlation: Stimulated Urinary C pep-
tide creatinine ratio in metabolic syndrome
Parameter Correlation coefficient r P Value
Fasting serum C peptide(nmol) 0.399 <0.01
Stimulated serum C peptide(nmol) 0.545 <0.01
Serum Insulin (MIU/L) 0.580 <0.01
HOMA IR 0.634 <0.01
Table 6. Pearson correlation: Stimulated Urinary C  
peptide creatinine ratio in metabolic syndrome
Parameter Correlation coefficient r P Value
Low Density Lipoprotein(mg/dl) 0.049 0.628
High Density Lipoprotein(mg/dl) -.163 0.105
Triglyceride(mg/dl) 0.735 <0.01
Uric acid(mg) 0.108 0.283
hs-CRP (mg) 0.758 <0.01
Fasting Blood Sugar(mg/dl) 0.331 <0.01
Post Prandial Blood Sugar(mg/dl) 0.386 <0.01
HBA1C (%) 0.105 0.298
Waist circumference (cm) 0.055 0.589
Waist:Hip Ratio 0.330 0.001
BMI (kg/m2) 0.142 0.16
DOI: https://doi.org/10.30564/jer.v3i2.3451
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Table 7. Multiple linear regression analysis with fasting 
urinary C peptide creatinine ratio as dependent variable
Dependent Variable: 
Fasting urinary C peptide 
creatinine ratio









Fasting serum C 
peptide(nmol)
.091 .886 .378 -.114 .296
Stimulated serum C 
peptide(nmol)
.405 3.677 <0.0001 .186 .624
Triglycerides(mg/dl) .009 4.931 <0.0001 .005 .012
Waist:Hip Ratio 2.584 1.851 .067 -.189 5.357
Fasting Blood Sugar (mg/
dl)
.012 1.994 .049 .000 .024
Fasting serum Insulin 
(MIU/L)
.119 3.833 <0.0001 .057 .180
Low Density Lipoprotein 
(mg/dl)
.000 -.170 .865 -.004 .003
High Density Lipoprotein 
(mg/dl)
.004 .469 .640 -.013 .022
Table 8. Multiple linear regression analysis with stimulat-
ed urinary C peptide creatinine ratio as dependent variable
Dependent Variable: 










Fasting serum C 
peptide(nmol)
.202 1.145 .255 -.148 .551
Stimulated serum C 
peptide(nmol)
.409 2.173 .032 .035 .782
Triglycerides(mg/dl) .019 6.338 <0.0001 .013 .025
Waist:Hip Ratio 2.454 1.030 .306 -2.276 7.183
Fasting Blood Sugar 
(mg/dl)
.019 1.842 .069 -.001 .039
Fasting serum insulin 
(MIU/L)
.231 4.382 <0.0001 .126 .336
Low Density Lipoprotein 
(mg/dl)
.000 .074 .941 -.006 .006
High Density 
Lipoprotein (mg/dl)
.021 1.410 .162 -.009 .051
Figure 1. Scatter plot: Fasting urinary c peptide creatinine ratio and Fasting Serum C Peptide
Figure 2. Scatter plot: Fasting urinary c peptide creatinine ratio and stimulated Serum C Peptide
DOI: https://doi.org/10.30564/jer.v3i2.3451
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Figure 3. Scatter plot: stimulated urinary c peptide creatinine ratio and Fasting Serum C Peptide
Figure 4. Scatter plot: stimulated urinary c peptide creatinine ratio and stimulated Serum C Peptide
Figure 5. ROC curve to identify patients with metabolic syndrome from control population
DOI: https://doi.org/10.30564/jer.v3i2.3451
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ROC curve to identify patients with metabolic syn-
drome from control population. The ROC curve identified 
a cut-off of fasting UCPCR ≥ 1.8 nmol/mmol and stim-
ulated UCPCR >2.8nmol/mmol for discriminating indi-
vidual with metabolic syndrome from control population 
(AUC 0.980 & 0.999) with 100% sensitivity and specific-
ity. The ROC curve identified a cut-off of HOMA IR ≥2.7 
for discriminating patients with metabolic syndrome from 
control population (AUC 0.66) with 30% sensitivity and 
95% specificity.
5. Discussion
Higher levels of central obesity are found among 
South Asians compared to European Whites with in-
sulin resistance is the central feature of the Metabolic 
syndrome. In our study, we found higher prevalence of 
metabolic syndrome in females (57%) as compared to 
males (43%), metabolic syndrome rate increases with in-
creasing age and was higher in elderly. In a similar study 
Seerat Beigh [10] and D S Prasad [11] found that female have 
higher prevalence of metabolic syndrome as compared 
to males and rates are higher in older age groups. On the 
other hand, Anthonia o ogbera [12] found that frequency 
of occurrence of the metabolic syndrome was similar for 
men and women and it increases with age in both sex-
es. Hypertriglyceridemia (95%) was the most common 
and hyperglycaemia (8%) least common component of 
metabolic syndrome in our study group. Also, individual 
component of metabolic syndrome was higher in female 
subjects as compared to males. Yasmeen khan [13] in her 
study found hyperglycaemia as the most common parame-
ter of metabolic syndrome followed by high Triglyceride, 
obesity, high blood pressure and low HDL. Seerat Beigh 
[10] found hypertension (38%) the most important metabolic 
syndrome parameters in the study subjects. Fasting urinary 
C peptide creatinine ratio and stimulated urinary C peptide 
creatinine ratio was higher in females as compared to male 
subjects (2.76±0.93 nmol/mmol vs 3.4±1.12 nmol/mmol, 
p<0.0001) & (5.66±2 nmol/mmol vs 4.79±1.56 nmol/mmol, 
p-0.02) which was very similar to study by Nicholas J 
Thomas [14] where he found that gender affects urinary C 
peptide excretion, with values 1.48-fold higher in women 
than men. This difference is because of gender differ-
ences in muscle mass in females as compared to males 
which leads to higher creatinine excretion (3.02±0.91 vs 
2.69±0.77, p-0.05). Similarly, Kulkarni et al [15] found that 
urinary C peptide creatinine ratio to be 1.5 times higher in 
women than men. Serum fasting insulin (12.85±2.43 IU 
vs 11.88±2.06 IU, p-0.04) and HOMA IR (2.65±0.62 vs 
2.39±0.6, p-0.04) was significantly higher in female sub-
jects than males which is similar to study by Chen-Huan 
Chen [16] in Chinese population. In our study fasting uri-
nary C peptide creatinine ratio was positively correlated 
with fasting serum C peptide (r-0.422, p<0.01), stimulated 
serum C peptide(r-0.663, p<0.01), fasting Serum Insulin 
(r-0.528, p<0.01), HOMA IR (r-0.626,p<0.01) and Waist: 
Hip ratio(r-0.421, p<0.01).Richard A Oram [17] found that 
in participants with normal renal function, fasting sec-
ond void UCPCR correlate with serum insulin, serum C 
peptide, and HOMA2- IR. kulkarni et al [15] and Jose E [18] 
similar to our study found urinary C peptide correlated 
with serum C peptide and serum insulin. Mary T [19] found 
that the fasting urinary C peptide may serve as a practical 
method for estimating the secretion rate of insulin. Studies 
on correlation between serum C peptide with blood sugar 
level shows positive correlation but there are sparse stud-
ies on urinary C peptide and blood sugar level. We found 
fasting urinary C peptide creatinine ratio to be positively 
correlated with FBS (r-0.384, p<0.01) and post prandial 
blood sugar (r-0.536, p-0.01). HsCRP and dyslipidaemia 
known to be associated with metabolic syndrome and its 
component but studies on urinary C peptide are lacking, 
our study showed significant positive correlation with 
hsCRP (r-0.783, p<0.01) and Serum triglyceride (r-0.721, 
p<0.01). Yanai Wang [20] on the other hand didn’t find 
correlation between fasting urinary C peptide creatinine 
ratio and triglyceride, HDL and LDL cholesterol. In our 
study stimulated urinary C peptide creatinine ratio has 
significant positive correlation with fasting serum C pep-
tide (r-0.399 p<0.01), stimulated serum C peptide (r-545 
p<0.01), fasting serum insulin (r-580 p<0.01), HOMA IR 
(r-634 p<0.01) which is in accordance with study con-
ducted by Richard A Oram [17] where he showed 120 min 
stimulated urinary C peptide creatinine ratio correlate 
with serum insulin and serum C-peptide. Mary T [19] found 
that post prandial and 24 hour urinary C peptide excretion 
correlate with secretion rate of insulin. Renato pasquali [21] 
while evaluating clinical application of the 24-h urinary 
C-peptide excretion rate found positive correlation with 
fasting and post prandial serum C peptide. Pokhriyal BN 
[22] found that home urine C-peptide determination could 
be practical alternative to serum C-peptide in detecting 
severe insulin deficiency. Although no study has correlat-
ed stimulated urinary C peptide with metabolic syndrome 
parameters, we found significant positive correlation be-
tween stimulated urinary C peptide creatinine ratio with 
waist: Hip ratio (r-0.330 p<0.01), serum triglyceride (r-735 
P<0.01), hsCRP (R-0.758 p<0.01), fasting blood sugar 
(r-331 p<0.01) and significant negative correlation with 
High density lipoprotein (r-241 p-0.016). We found that 
on multivariate analysis both fasting and stimulated uri-
nary C peptide creatinine ratio correlate with stimulated 
DOI: https://doi.org/10.30564/jer.v3i2.3451
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serum C peptide as compared to fasting serum C peptide. 
Literature also suggests that stimulated serum C peptide 
to be more accurate as compared to fasting serum C pep-
tide. The receiver operating characteristic (ROC) curve of 
fasting and stimulated urinary C peptide creatinine ratio 
for the diagnosis of Metabolic syndrome was depicted and 
the area under the curve (AUC) was calculated (Figure 5). 
The ROC curve identified a cut-off of fasting UCPCR ≥ 
1.8 nmol/mmol and stimulated UCPCR >2.8 nmol/mmol 
for discriminating individual with metabolic syndrome 
from control population (AUC 0.980 & 0.999) with 100% 
sensitivity and specificity. HOMA IR cut-off of 2.5 is 
established for the diagnosis of metabolic syndrome with 
sensitivity of >70% and specificity of >60% as shown by 
previous studies in Indian adolescents [23]. The ROC curve 
identified a cut-off of HOMA IR ≥2.7 for discriminating 
patients with metabolic syndrome from control population 
(AUC 0.66) with 30% sensitivity and 95% specificity.
This study opens the door for future clinical research 
to establish additional criteria for diagnosis of Metabolic 
syndrome and to assist in refining the definition of Met-
abolic syndrome. In view of lack of comparative studies 
on urinary C peptide creatinine ratio in patients with 
metabolic syndrome, small sample size and observational 
design it is difficult to establish clinical significance of 
subtle abnormalities noticed in this study. Further studies 
are needed to verify the finding of our studies
In conclusions, urinary C-peptide is a useful indicator 
of beta cell function owing to sensitivity, reproducibility 
and convenience of the test. Urinary C peptide creatinine 
ratio is feasible and reliable marker of insulin secretion 
and insulin resistance in patient with metabolic syndrome. 
Fasting and stimulated urinary C peptide creatinine ratio 
correlate positively with markers of metabolic syndrome 
and can be used for differentiating individuals with and 
without metabolic syndrome with high sensitivity and 
specificity. Urinary C peptide creatinine ratio may be in-
corporated in diagnostic criteria in the future. Similarly, 
HOMA IR of >2.7 can also be used as cut off in individual 
at high risk of metabolic syndrome. Further work is need-
ed to examine the potential clinical uses of this novel test 
and to verify the finding of our study.
6. Strength and Limitation
Very few studies have been done on fasting and stimu-
lated urinary C peptide creatinine ratio and its correlation 
in metabolic syndrome.
This study opens the door for future clinical research 
to establish additional criteria for diagnosis of Metabolic 
syndrome and to assist in refining the definition of Meta-
bolic syndrome.
In view of lack of comparative studies on urinary C 
peptide creatinine ratio in patients with metabolic syn-
drome, small sample size and observational design it is 
difficult to establish clinical significance of subtle abnor-
malities noticed in this study. 
Further studies are needed to verify the finding of our 
studies.
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